• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Dr. Gao on treating re-emerged PARPi-resistant prostate cancer

Video

“Some potential…combination therapy may be valuable, such as combining with a checkpoint inhibitor or some target senescence because this resistance involves those kinds of mechanisms,” says Allen C. Gao, MD, PhD.

In this video, Allen C. Gao, MD, PhD, discusses the possibility of re-emerged PARP inhibitor resistant prostate cancer and what future studies should do to continue developing treatments. Gao was the senior author on the study, “Resistance to olaparib is dependent on re-emergence from G2/M arrested senescence,” which was presented at the 2021 AUA Annual Meeting.

Gao is the Ralph de Vere White professor in the department of urologic surgery and director of urologic research at University of California, Davis.

Related Videos
Michael S. Cookson, MD, MMHC, FACS, answers a question during a Zoom video interview
Related Content
© 2024 MJH Life Sciences

All rights reserved.